Sensory Cloud has announced positive results from the Phase II REACH trial of SC0023 conducted at King Saud University Medical City in Saudi Arabia, revealing a reduction in cough rates.
SC0023 is a therapeutic aerosol that contains ions endogenous to human airways and is intended to treat subjects with refractory chronic cough (RCC).
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
REACH trial principal investigator Dr Kholood Altassan said: “Chronic cough is a major unmet healthcare need afflicting an estimated 10% of the adult human population globally.”
Sensory Cloud founder and CEO David Edwards said: “By conducting the REACH trial in Riyadh, we wished to explore whether chronic cough behaviour and treatment via daily laryngeal rehydration would follow patterns we had previously seen in a recent exploratory trial at Imperial College London, notwithstanding the drier and dustier air in Riyadh.
“That chronic cough behaviour and treatment efficacy were indistinguishable between the London and Riyadh sites may point to the predominance of time spent within indoor arid-air living environments and the commonality of arid indoor atmospheric conditions.”
The crossover design revealed therapeutic period effects, limiting primary efficacy analysis to the initial dosing period as a parallel segment design.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataPost hoc analyses considering investigational product adherence demonstrated a 34% placebo-adjusted cough rate reduction in six participants.
Hyfe CoughMonitor watch monitoring revealed persistent suppression of cough rate continuing several weeks after dosing, despite SC0023’s three-hour endogenous ion clearance time.
This persistence aligns with treatment decompression as well as down-regulation of mechano-sensitive ion channels.
Based on these outcomes, Sensory Cloud plans to carry out a follow-up Phase II study at several centres in Belfast, Ireland, and London, UK.
